MX2011002936A - Formulaciones liquidas de bendamustina. - Google Patents
Formulaciones liquidas de bendamustina.Info
- Publication number
- MX2011002936A MX2011002936A MX2011002936A MX2011002936A MX2011002936A MX 2011002936 A MX2011002936 A MX 2011002936A MX 2011002936 A MX2011002936 A MX 2011002936A MX 2011002936 A MX2011002936 A MX 2011002936A MX 2011002936 A MX2011002936 A MX 2011002936A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- bendamustine
- approximately
- pharmaceutically acceptable
- aqueous
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229960002707 bendamustine Drugs 0.000 title claims abstract description 71
- 239000012669 liquid formulation Substances 0.000 title abstract description 10
- 239000003880 polar aprotic solvent Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 113
- 238000009472 formulation Methods 0.000 claims description 96
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 59
- 239000003586 protic polar solvent Substances 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 239000008139 complexing agent Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 150000003140 primary amides Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 23
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- -1 polybutylene Polymers 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940066958 treanda Drugs 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000795130 Homo sapiens Trehalase Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10007408P | 2008-09-25 | 2008-09-25 | |
| PCT/US2009/058023 WO2010036702A1 (en) | 2008-09-25 | 2009-09-23 | Liquid formulations of bendamustine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011002936A true MX2011002936A (es) | 2011-04-11 |
Family
ID=41559533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011002936A MX2011002936A (es) | 2008-09-25 | 2009-09-23 | Formulaciones liquidas de bendamustina. |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US20110190363A1 (enExample) |
| EP (2) | EP2326306A1 (enExample) |
| JP (1) | JP5670335B2 (enExample) |
| CN (2) | CN104224703A (enExample) |
| AU (5) | AU2009296734B2 (enExample) |
| CA (1) | CA2735899A1 (enExample) |
| HK (1) | HK1211462A1 (enExample) |
| MX (1) | MX2011002936A (enExample) |
| WO (1) | WO2010036702A1 (enExample) |
Families Citing this family (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099724A2 (en) * | 2004-04-13 | 2005-10-27 | Parallel Solutions, Inc. | Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US20070086958A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Formation of medically useful gels comprising microporous particles and methods of use |
| BRPI0807350A2 (pt) * | 2007-02-05 | 2014-05-06 | Univ Singapore | Receptor de quitocina putativa e métodos para uso do mesmo |
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CN104224703A (zh) | 2008-09-25 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
| WO2010090988A2 (en) * | 2009-02-06 | 2010-08-12 | The Procter & Gamble Company | Collapsible water-containing capsules |
| MX2011010673A (es) * | 2009-04-10 | 2012-02-21 | Abraxis Bioscience Llc | Formulaciones de nanoparticulas y usos de las mismas. |
| EP2427179A4 (en) | 2009-05-04 | 2013-09-11 | Psivida Inc | POROUS PARTICLES FOR THE RELEASE OF SILICIUM MEDICINES |
| WO2010144675A1 (en) | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| US11000711B2 (en) * | 2009-12-29 | 2021-05-11 | W. R. Grace & Co.-Conn. | Compositions for forming films having a desired degree of obscuration and methods of making and using the same |
| WO2011094565A1 (en) | 2010-01-28 | 2011-08-04 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US10729625B2 (en) * | 2010-02-04 | 2020-08-04 | Isp Investments Llc | Self adapting polymers for anhydrous sunscreen formulations |
| MX2012009632A (es) * | 2010-02-18 | 2012-09-28 | Athenix Corp | Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, axmi225z y metodos para su uso. |
| WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| AR080201A1 (es) * | 2010-02-18 | 2012-03-21 | Athenix Corp | Genes delta-endotoxinicos de bacillus thuringiensis (axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, y axmi231), y metodos para su uso |
| KR101982126B1 (ko) | 2010-03-08 | 2019-05-27 | 몬산토 테크놀로지 엘엘씨 | 식물에서 유전자 조절을 위한 폴리뉴클레오타이드 분자 |
| FR2958155B1 (fr) * | 2010-04-02 | 2012-04-20 | Oreal | Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras |
| WO2011137563A1 (en) | 2010-05-07 | 2011-11-10 | Unilever Plc | High solvent content emulsions |
| EA033088B1 (ru) | 2010-06-04 | 2019-08-30 | Монсанто Текнолоджи Ллс | Трансгенное событие mon 88302 у вида brassica и способы его применения |
| WO2011160170A1 (en) * | 2010-06-21 | 2011-12-29 | Peter Maccallum Cancer Institute | Stimulating immune response |
| US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| US8802933B2 (en) * | 2010-08-19 | 2014-08-12 | Pioneer Hi Bred International Inc | Bacillus thuringiensis gene with lepidopteran activity |
| CN103491961B (zh) * | 2010-10-28 | 2018-01-02 | 艾库斯制药有限公司 | 阿立哌唑组合物和用于其经皮给药的方法 |
| US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
| RU2640918C2 (ru) | 2010-11-01 | 2018-01-12 | Псивида Юэс, Инк. | Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов |
| WO2012122535A2 (en) | 2011-03-10 | 2012-09-13 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
| US20120311734A1 (en) * | 2011-06-04 | 2012-12-06 | The Texas A&M University System | Potato transformation compositions, systems, methods, microorganisms, and plants |
| JP2013032332A (ja) * | 2011-07-01 | 2013-02-14 | Lintec Corp | 免疫賦活剤 |
| WO2013023992A1 (en) * | 2011-08-12 | 2013-02-21 | Bayer Cropscience Nv | Guard cell-specific expression of transgenes in cotton |
| CA2848685A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control comprising topical application of a glutamine synthetase polynucleotide |
| BR112014005975A8 (pt) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | Método de controle de planta, método de redução de expressão de um gene pds em uma planta, cassete de expressão microbiana, método de fazer um polinucleotídeo, método de identificação de polinucleotídeos, e composições para controle de erva daninha |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| EP3434780A1 (en) | 2011-09-13 | 2019-01-30 | Monsanto Technology LLC | Methods and compositions for weed control |
| BR112014005958A2 (pt) | 2011-09-13 | 2020-10-13 | Monsanto Technology Llc | métodos e composições químicas agrícolas para controle de planta, método de redução de expressão de um gene accase em uma planta, cassete de expressão microbiana, método para fazer um polinucleotídeo, método de identificação de polinucleotídeos úteis na modulação de expressão do gene accase e composição herbicida |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
| EP2758052B9 (en) * | 2011-09-18 | 2019-03-27 | Euro-Celtique S.A. | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
| ES2613838T3 (es) | 2011-09-26 | 2017-05-26 | Fresenius Kabi Oncology Ltd | Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina |
| BR112014007366B1 (pt) * | 2011-10-05 | 2020-09-15 | Dupont Nutrition Usa, Inc | Processo para fabricar uma composição estabilizadora compreendendo extrusão em duas etapas, composição estabilizadora de celulose microcristalina e produto alimentício comestível e suspensão industrial compreendendo a mesma |
| US9492363B1 (en) * | 2012-01-16 | 2016-11-15 | American Spraytech, L.L.C. | Aerosol sprayable color composition |
| US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| AU2013212005A1 (en) * | 2012-01-27 | 2014-07-31 | Agile Therapeutics, Inc. | Transdermal hormone delivery |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| CA2864118A1 (en) * | 2012-02-14 | 2013-08-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| HRP20230276T1 (hr) | 2012-03-20 | 2023-04-28 | Eagle Pharmaceuticals, Inc. | Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni |
| ES2972227T3 (es) * | 2012-03-20 | 2024-06-11 | Eagle Pharmaceuticals Inc | Formulaciones de bendamustina |
| WO2013148919A1 (en) | 2012-03-30 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of multiple myeloma |
| CN104619843B (zh) | 2012-05-24 | 2020-03-06 | A.B.种子有限公司 | 用于使基因表达沉默的组合物和方法 |
| US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| EP2879715B1 (en) * | 2012-08-03 | 2023-03-29 | MSM Innovations, Inc. | Method and kit for bowel preparation |
| US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US10584381B2 (en) | 2012-08-14 | 2020-03-10 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| CN114891871A (zh) | 2012-08-14 | 2022-08-12 | 10X基因组学有限公司 | 微胶囊组合物及方法 |
| US9801859B2 (en) | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
| US9617297B2 (en) * | 2012-10-11 | 2017-04-11 | The Regents Of The University Of California | Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves |
| BR112015008706A2 (pt) | 2012-10-18 | 2018-02-06 | Monsanto Technology Llc | métodos e composições para controle de praga de plantas |
| EP2917183A1 (en) * | 2012-11-12 | 2015-09-16 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
| ES2564274T3 (es) * | 2012-11-19 | 2016-03-21 | Oncotec Pharma Produktion Gmbh | Procedimiento para la preparación de una composición liofilizada |
| EP3567116A1 (en) | 2012-12-14 | 2019-11-13 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US9206436B2 (en) * | 2012-12-20 | 2015-12-08 | Ut-Battelle, Llc | Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| UY35251A (es) | 2013-01-01 | 2014-07-31 | Seeds Ltd Ab | MOLÉCULAS DE dsRNA AISLADAS Y MÉTODOS PARA USARLAS PARA SILENCIAR MOLÉCULAS DIANA DE INTERÉS |
| US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| KR20230003659A (ko) | 2013-02-08 | 2023-01-06 | 10엑스 제노믹스, 인크. | 폴리뉴클레오티드 바코드 생성 |
| US8961680B2 (en) * | 2013-03-08 | 2015-02-24 | Tbf Environmental Technology Inc. | Solvent formulations |
| US20140271764A1 (en) * | 2013-03-12 | 2014-09-18 | Psivida Us, Inc. | Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents |
| CA2905027A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
| AU2014248958A1 (en) | 2013-03-13 | 2015-10-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
| CN105025928A (zh) | 2013-03-15 | 2015-11-04 | 普西维达公司 | 用于递送治疗剂的可生物蚀解的硅基组合物 |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| US20140275267A1 (en) * | 2013-03-15 | 2014-09-18 | Maria Beug-Deeb Inc. Dba T&M Associates | Methods and compositions for cleaning and disinfecting surfaces |
| CA2817728A1 (en) * | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| MX359191B (es) * | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
| CN103351347A (zh) * | 2013-07-29 | 2013-10-16 | 东南大学 | 盐酸苯达莫司汀杂质dce的制备方法 |
| CN109953954A (zh) | 2013-08-27 | 2019-07-02 | V·沃道里斯 | 苯达莫司汀医药组合物 |
| LT3421033T (lt) * | 2013-10-07 | 2022-11-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Atazanaviro ir kobicistato kompozicija, skirta živ gydymui |
| WO2015054550A1 (en) * | 2013-10-11 | 2015-04-16 | Luitpold Pharmaceuticals, Inc. | Bendamustine pharmaceutical compositions |
| AR098295A1 (es) | 2013-11-04 | 2016-05-26 | Monsanto Technology Llc | Composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| IN2014CH00151A (enExample) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
| AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
| CA2941632C (en) * | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
| US9694361B2 (en) | 2014-04-10 | 2017-07-04 | 10X Genomics, Inc. | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US10988764B2 (en) | 2014-06-23 | 2021-04-27 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| KR20170026383A (ko) | 2014-06-26 | 2017-03-08 | 10엑스 제노믹스, 인크. | 핵산 서열의 분석 |
| US12312640B2 (en) | 2014-06-26 | 2025-05-27 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| EP4574974A3 (en) | 2014-06-26 | 2025-10-08 | 10x Genomics, Inc. | Methods of analyzing nucleic acids from individual cells or cell populations |
| EP3167049A4 (en) | 2014-07-08 | 2017-11-29 | MIMEDX Group Inc. | Micronized wharton's jelly |
| US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
| CN114009454A (zh) | 2014-07-29 | 2022-02-08 | 孟山都技术公司 | 用于控制昆虫害虫的组合物和方法 |
| KR102428675B1 (ko) | 2014-08-06 | 2022-08-02 | 엑스에리스 파머수티클스, 인크. | 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법 |
| DK3191083T3 (da) * | 2014-09-11 | 2021-04-19 | Gelita Ag | Gelatine-/pektinpartikler |
| BR112017005505B1 (pt) | 2014-09-17 | 2022-09-06 | Arxada, LLC | Composição de peróxido de hidrogênio de solução desinfetante pronta para uso |
| JP2017532042A (ja) | 2014-10-29 | 2017-11-02 | １０エックス ゲノミクス，インコーポレイテッド | 標的化核酸配列決定のための方法及び組成物 |
| US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
| US9603930B2 (en) * | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
| EA201791542A1 (ru) * | 2015-01-06 | 2018-03-30 | Осаму Ямада | Лекарственный препарат, устройство для лечения заболеваний крови, косметическое средство, продукт питания и напиток, использующий вещество, полученное методом синтеза в процессе горения |
| AU2016207023B2 (en) | 2015-01-12 | 2019-12-05 | 10X Genomics, Inc. | Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same |
| RU2723049C2 (ru) | 2015-01-22 | 2020-06-08 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
| AU2016222719B2 (en) | 2015-02-24 | 2022-03-31 | 10X Genomics, Inc. | Methods for targeted nucleic acid sequence coverage |
| EP4286516A3 (en) | 2015-02-24 | 2024-03-06 | 10X Genomics, Inc. | Partition processing methods and systems |
| WO2016137804A1 (en) | 2015-02-25 | 2016-09-01 | The Procter & Gamble Company | Fibrous structures comprising a surface softening composition |
| US20160303043A1 (en) * | 2015-04-16 | 2016-10-20 | Kate Somerville Skincare, LLC | Self-foaming compositions and methods |
| US10883103B2 (en) | 2015-06-02 | 2021-01-05 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
| US10655136B2 (en) | 2015-06-03 | 2020-05-19 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| US20170009184A1 (en) | 2015-07-10 | 2017-01-12 | The Procter & Gamble Company | Fabric care composition comprising metathesized unsaturated polyol esters |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| KR102723865B1 (ko) | 2015-12-04 | 2024-10-29 | 10엑스 제노믹스, 인크. | 핵산 분석을 위한 방법 및 조성물 |
| CN110772480B (zh) * | 2016-03-25 | 2022-05-17 | 南京百劲企业管理咨询有限公司 | 苯达莫司汀药剂组合物及应用 |
| WO2017197343A2 (en) | 2016-05-12 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic on-chip filters |
| WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
| JP6923564B2 (ja) | 2016-07-08 | 2021-08-18 | ザ ジレット カンパニー リミテッド ライアビリティ カンパニーＴｈｅ Ｇｉｌｌｅｔｔｅ Ｃｏｍｐａｎｙ Ｌｌｃ | メタセシス化不飽和ポリオールエステルを含む除毛装置のための液体組成物 |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| DE102016223333A1 (de) * | 2016-11-24 | 2018-05-24 | Henkel Ag & Co. Kgaa | Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer |
| US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| EP4310183B1 (en) | 2017-01-30 | 2025-07-09 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
| US12264411B2 (en) | 2017-01-30 | 2025-04-01 | 10X Genomics, Inc. | Methods and systems for analysis |
| IL268997B2 (en) | 2017-03-01 | 2023-09-01 | Arena Pharm Inc | Preparations containing pgi2 receptor agonists and processes for their preparation |
| US10398670B2 (en) * | 2017-04-24 | 2019-09-03 | Knoze Jr. Corporation | Oral microbiota promotion for oral and/or sinus infections |
| US10844372B2 (en) | 2017-05-26 | 2020-11-24 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
| CN116064732A (zh) | 2017-05-26 | 2023-05-05 | 10X基因组学有限公司 | 转座酶可接近性染色质的单细胞分析 |
| CN117085022A (zh) | 2017-06-02 | 2023-11-21 | Xeris药物公司 | 抗沉淀的小分子药物制剂 |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| US10471033B2 (en) * | 2017-09-15 | 2019-11-12 | Knoze Jr. Corporation | Oral microbiota promotion for immune system associated inflammations |
| US12151014B2 (en) * | 2017-09-18 | 2024-11-26 | Mast Industries (Far East) Limited | Gloss lip balm formulation |
| AU2018346395A1 (en) * | 2017-10-05 | 2020-04-30 | Mecox Curemed Co., Ltd. | Oral bendamustine formulations |
| WO2019097413A1 (en) * | 2017-11-15 | 2019-05-23 | Intas Pharmaceuticals Ltd. | Stable non-aqueous pharmaceutical compositions |
| EP3625361A1 (en) | 2017-11-15 | 2020-03-25 | 10X Genomics, Inc. | Functionalized gel beads |
| WO2019099908A1 (en) | 2017-11-17 | 2019-05-23 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
| JP7464995B2 (ja) * | 2018-03-29 | 2024-04-10 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液体薬学的製剤 |
| EP3775271B1 (en) | 2018-04-06 | 2025-03-12 | 10X Genomics, Inc. | Systems and methods for quality control in single cell processing |
| EP3836921B1 (en) | 2018-08-17 | 2025-10-08 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| EP3897626B1 (en) | 2018-12-18 | 2025-09-10 | Mundipharma International Corporation Limited | Tinostamustine for treating multiple myeloma |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
| CA3180338A1 (en) * | 2020-04-15 | 2021-10-21 | Kashiv Biosciences, Llc | Stable ready to dilute formulations of carfilzomib |
| US11707450B1 (en) | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (enExample) | 1903-10-08 | 1905-03-16 | ||
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| DE3446873A1 (de) * | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
| US5051257A (en) * | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| US5162115A (en) * | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| DD293808A5 (de) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| ATE139900T1 (de) * | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5741523A (en) * | 1993-10-27 | 1998-04-21 | Pharmacia & Upjohn Company | Stabilized prostaglandin E1 |
| US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
| US5955504A (en) * | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
| DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| JP2002520282A (ja) * | 1998-07-09 | 2002-07-09 | フランシス エイ． ナーデラ， | 慢性リンパ性白血病の処置のための方法および組成物 |
| US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
| US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
| DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
| US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
| KR20040025881A (ko) * | 2000-12-11 | 2004-03-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 개선된 흡수성을 갖는 의약 조성물 |
| PL362979A1 (en) * | 2000-12-11 | 2004-11-02 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
| DK1435877T3 (da) * | 2001-10-15 | 2009-08-03 | Hemoteq Ag | Overtrækning af stents for at forhindre restenose |
| US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| AU2003221517B2 (en) | 2002-03-22 | 2010-02-18 | Christian Straka | Cytocapacity test |
| EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| EP1501565B1 (de) | 2002-05-09 | 2006-11-02 | Hemoteq GmbH | Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen |
| US20040096436A1 (en) * | 2002-08-02 | 2004-05-20 | Regents Of The University Of California | Methods for inhibiting protein kinases in cancer cells |
| DE10304403A1 (de) | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| EP1594900A2 (en) * | 2003-02-14 | 2005-11-16 | Salmedix, Inc. | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| KR20060052880A (ko) * | 2003-07-25 | 2006-05-19 | 와이어쓰 | 동결건조된 ｃｃｉ- 779 제형 |
| EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
| CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US7872050B2 (en) * | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CN104224703A (zh) | 2008-09-25 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
-
2009
- 2009-09-23 CN CN201410449785.0A patent/CN104224703A/zh active Pending
- 2009-09-23 WO PCT/US2009/058023 patent/WO2010036702A1/en not_active Ceased
- 2009-09-23 CA CA2735899A patent/CA2735899A1/en not_active Abandoned
- 2009-09-23 MX MX2011002936A patent/MX2011002936A/es active IP Right Grant
- 2009-09-23 EP EP09740213A patent/EP2326306A1/en not_active Withdrawn
- 2009-09-23 JP JP2011529180A patent/JP5670335B2/ja active Active
- 2009-09-23 AU AU2009296734A patent/AU2009296734B2/en active Active
- 2009-09-23 EP EP15152744.7A patent/EP2889029A1/en not_active Withdrawn
- 2009-09-23 CN CN200980137977.5A patent/CN102164579B/zh active Active
-
2011
- 2011-03-15 US US13/048,325 patent/US20110190363A1/en not_active Abandoned
- 2011-12-01 HK HK15111733.2A patent/HK1211462A1/en unknown
-
2012
- 2012-01-31 US US13/362,430 patent/US8344006B2/en active Active
- 2012-10-19 US US13/655,498 patent/US20130041004A1/en not_active Abandoned
-
2013
- 2013-11-20 US US14/084,768 patent/US20140080881A1/en not_active Abandoned
-
2014
- 2014-01-09 US US14/151,242 patent/US20140128443A1/en not_active Abandoned
- 2014-03-21 US US14/221,422 patent/US20140206733A1/en not_active Abandoned
-
2015
- 2015-07-31 AU AU2015207940A patent/AU2015207940B2/en active Active
- 2015-07-31 US US14/814,570 patent/US20150335750A1/en not_active Abandoned
-
2016
- 2016-05-18 AU AU2016203246A patent/AU2016203246B2/en active Active
- 2016-10-19 AU AU2016247123A patent/AU2016247123A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,182 patent/US20180125824A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202107A patent/AU2018202107A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/835,562 patent/US20210008035A1/en not_active Abandoned
- 2020-09-09 US US17/015,175 patent/US20210113530A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150335750A1 (en) | 2015-11-26 |
| AU2015207940A1 (en) | 2015-08-20 |
| CN104224703A (zh) | 2014-12-24 |
| CN102164579A (zh) | 2011-08-24 |
| AU2016203246B2 (en) | 2017-09-21 |
| US8344006B2 (en) | 2013-01-01 |
| CA2735899A1 (en) | 2010-04-01 |
| US20210113530A1 (en) | 2021-04-22 |
| AU2009296734A1 (en) | 2010-04-01 |
| AU2016247123A1 (en) | 2016-11-03 |
| EP2326306A1 (en) | 2011-06-01 |
| JP5670335B2 (ja) | 2015-02-18 |
| HK1211462A1 (en) | 2016-05-27 |
| JP2012503666A (ja) | 2012-02-09 |
| US20180125824A1 (en) | 2018-05-10 |
| CN102164579B (zh) | 2014-10-15 |
| AU2009296734B2 (en) | 2016-02-18 |
| US20140206733A1 (en) | 2014-07-24 |
| AU2015207940B2 (en) | 2016-11-10 |
| US20140128443A1 (en) | 2014-05-08 |
| US20210008035A1 (en) | 2021-01-14 |
| WO2010036702A1 (en) | 2010-04-01 |
| US20120129904A1 (en) | 2012-05-24 |
| US20110190363A1 (en) | 2011-08-04 |
| EP2889029A1 (en) | 2015-07-01 |
| US20130041004A1 (en) | 2013-02-14 |
| US20140080881A1 (en) | 2014-03-20 |
| AU2016203246A1 (en) | 2016-06-09 |
| AU2018202107A1 (en) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015207940B2 (en) | Liquid Formulations of Bendamustine | |
| US9572888B2 (en) | Formulations of bendamustine | |
| US20140142153A1 (en) | Bendamustine formulations | |
| JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
| WO2017175098A1 (en) | Stable liquid pharmaceutical formulations of bendamustine | |
| US9801859B2 (en) | Bendamustine formulations | |
| WO2016005995A2 (en) | Glycol free stable liquid compositions of bendamustine | |
| WO2014202553A1 (en) | Lyophilized formulations of bendamustine hydrochloride | |
| US20140275122A1 (en) | Voriconazole Formulations | |
| US20150087681A1 (en) | Bendamustine HCL Stable Lyophilized Formulations | |
| WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
| WO2025165852A1 (en) | Liquid formulations of lurbinectedin | |
| WO2014170769A2 (en) | Bendamustine lyophilized pharmaceutical compositions | |
| EP3231427A1 (en) | Aqueous liquid agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |